Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
0.8149
0.00 (0.00%)
May 9, 2025, 10:38 AM - Market open
Silo Pharma Revenue
In the year 2024, Silo Pharma had annual revenue of $72.10K. Silo Pharma had revenue of $18.03K in the quarter ending December 31, 2024.
Revenue (ttm)
$72.10K
Revenue Growth
n/a
P/S Ratio
41.60
Revenue / Employee
$24,034
Employees
3
Market Cap
3.65M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SILO News
- 9 days ago - Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study - GlobeNewsWire
- 11 days ago - Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug - GlobeNewsWire
- 6 weeks ago - Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment - GlobeNewsWire
- 2 months ago - Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment - GlobeNewsWire
- 2 months ago - Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment - GlobeNewsWire
- 3 months ago - Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia - GlobeNewsWire
- 3 months ago - Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment - GlobeNewsWire
- 4 months ago - Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain - GlobeNewsWire